Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 180

1.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 May 8. doi: 10.1038/nm.4333. [Epub ahead of print]

PMID:
28481359
2.

Discharge to Subacute Rehabilitation Facilities Does Not Benefit Patients Hospitalized With Progressive Gastrointestinal Cancer.

Desai AV, Epstein AS, Colbert LE, Saltz LB.

J Pain Symptom Manage. 2017 Apr 22. pii: S0885-3924(17)30157-4. doi: 10.1016/j.jpainsymman.2017.03.006. [Epub ahead of print] No abstract available.

PMID:
28438586
3.

Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations.

Hechtman JF, Middha S, Stadler ZK, Zehir A, Berger MF, Vakiani E, Weiser MR, Ladanyi M, Saltz LB, Klimstra DS, Shia J.

Fam Cancer. 2017 Apr 12. doi: 10.1007/s10689-017-9993-x. [Epub ahead of print] No abstract available.

PMID:
28405781
4.

Predicted Vitamin D Status and Colon Cancer Recurrence and Mortality in CALGB 89803 (Alliance).

Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K.

Ann Oncol. 2017 Mar 15. doi: 10.1093/annonc/mdx109. [Epub ahead of print]

PMID:
28327908
5.

Reply to G. Le Flahec et al.

Stadler ZK, Saltz LB.

J Clin Oncol. 2017 Jan 20;35(3):378. doi: 10.1200/JCO.2016.69.9413. Epub 2016 Oct 24. No abstract available.

PMID:
28095264
6.

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.

Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.

Oncologist. 2017 Jan;22(1):107-114. doi: 10.1634/theoncologist.2016-0215. Epub 2016 Nov 7.

PMID:
27821793
7.

Bevacizumab in colorectal cancer: it should have worked.

Saltz LB.

Lancet Oncol. 2016 Nov;17(11):1469-1470. doi: 10.1016/S1470-2045(16)30213-3. Epub 2016 Sep 19. No abstract available.

PMID:
27660191
8.

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

Saltz LB.

Cancer J. 2016 May-Jun;22(3):232-5. doi: 10.1097/PPO.0000000000000194. Review.

PMID:
27341604
9.

Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.

Cercek A, Park V, Yaeger R, Reidy-Lagunes D, Kemeny NE, Stadler ZK, Segal NH, Varghese A, Saltz LB.

J Oncol Pract. 2016 May;12(5):e548-53. doi: 10.1200/JOP.2015.008417. Epub 2016 Apr 12.

PMID:
27072569
10.

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

Stadler ZK, Battaglin F, Middha S, Hechtman JF, Tran C, Cercek A, Yaeger R, Segal NH, Varghese AM, Reidy-Lagunes DL, Kemeny NE, Salo-Mullen EE, Ashraf A, Weiser MR, Garcia-Aguilar J, Robson ME, Offit K, Arcila ME, Berger MF, Shia J, Solit DB, Saltz LB.

J Clin Oncol. 2016 Jun 20;34(18):2141-7. doi: 10.1200/JCO.2015.65.1067. Epub 2016 Mar 28.

11.

A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.

Segal NH, Gada P, Senzer N, Gargano MA, Patchen ML, Saltz LB.

Clin Colorectal Cancer. 2016 Sep;15(3):222-7. doi: 10.1016/j.clcc.2016.02.013. Epub 2016 Feb 13.

PMID:
26975418
12.

Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters.

Hötker AM, Tarlinton L, Mazaheri Y, Woo KM, Gönen M, Saltz LB, Goodman KA, Garcia-Aguilar J, Gollub MJ.

Eur Radiol. 2016 Dec;26(12):4303-4312. Epub 2016 Mar 5.

PMID:
26945761
13.

Overspending driven by oversized single dose vials of cancer drugs.

Bach PB, Conti RM, Muller RJ, Schnorr GC, Saltz LB.

BMJ. 2016 Feb 29;352:i788. doi: 10.1136/bmj.i788. No abstract available.

PMID:
26932932
14.

Genetic Screening in All Young Patients With Colorectal Cancer?

Saltz LB.

J Clin Oncol. 2016 May 1;34(13):1560. doi: 10.1200/JCO.2015.65.9847. Epub 2016 Feb 29. No abstract available.

PMID:
26926689
15.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Apr 10;34(11):1182-9. doi: 10.1200/JCO.2015.65.1158. Epub 2016 Feb 8.

16.

The Value of Considering Cost, and the Cost of Not Considering Value.

Saltz LB.

J Clin Oncol. 2016 Mar 1;34(7):659-60. doi: 10.1200/JCO.2015.64.7867. Epub 2015 Dec 14. No abstract available.

PMID:
26668345
17.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.

J Clin Oncol. 2016 Jan 10;34(2):144-50. doi: 10.1200/JCO.2015.61.6441. Epub 2015 Oct 26.

18.

Perspectives on Cost and Value in Cancer Care.

Saltz LB.

JAMA Oncol. 2016 Jan;2(1):19-21. doi: 10.1001/jamaoncol.2015.4191. No abstract available.

PMID:
26501848
19.

Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.

Saltz LB.

J Clin Oncol. 2015 Nov 10;33(32):3843-4. doi: 10.1200/JCO.2015.62.9287. Epub 2015 Aug 24. No abstract available.

PMID:
26304894
20.

Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2015 Nov 1;33(31):3598-607. doi: 10.1200/JCO.2015.61.5062. Epub 2015 Aug 17.

Supplemental Content

Loading ...
Support Center